BUZZ-Biohaven jumps as cancer treatment shows promise in early-stage trial** Shares of drugmaker Biohaven BHVN.N rise 8.5% to $11.50
** Co says its experimental therapy, BHV-1510, in combination with Regeneron Pharmaceuticals' REGN.O Libtayo, showed efficacy and manageable safety across several tumors in an early-stage trial
** Co says patients receiving the treatment every three weeks showed a 72.7% confirmed response
** The combination therapy is being tested among pre-treated patients with advanced cancers - BHVN
** RBC Capital Markets says it "sees these efficacy and safety results as promising"
** Including session moves, stock down 69.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.